Your IP: 34.239.158.107 United States Near: Houston, Texas, United States

Lookup IP Information

2 3 4 5 6 7 8 Next

Below is the list of all allocated IP address in 139.196.0.0 - 139.196.255.255 network range, sorted by latency.

Gavilimomab ? Monoclonal antibody Type Whole antibody Source Mouse Target CD147 Clinical data Pregnancy cat.  ? Legal status  ? Identifiers CAS number 244096-20-6 ATC code None Chemical data Formula  ?  Y(what is this?)  [1] Gavilimomab (also known as ABX-CBL) is a mouse monoclonal antibody intended for use as an immunosuppressive biologic treatment of glucocorticoid-resistant graft versus host disease. It binds to the antigen CD147.[1] Gavilimomab proved slightly less effective than standard antithymocyte globulin therapy.[2] It was originally developed by Abgenix,[1] which was later acquired by Amgen. References ^ a b findarticles.com: Sangstat to Provide Clinical Development Update At JP Morgan H&Q Conference in San Francisco ^ Macmillan, ML; Couriel, D; Weisdorf, DJ; Schwab, G; Havrilla, N; Fleming, TR; Huang, S; Roskos, L et al. (Mar 2007). "A phase 2/3 multicenter randomized clinical trial of ABX-CBL versus ATG as secondary therapy for steroid-resistant acute graft-versus-host disease.". Blood 109 (6): 2657-62. doi:10.1182/blood-2006-08-013995. PMID 17110457.  v · d · eImmunomodulators: Immunosuppressive drugs / Immunosuppressants (L04) Intracellular (initiation) Antimetabolites purine synthesis inhibitor: Azathioprine • Mycophenolic acid pyrimidine synthesis inhibitor: Leflunomide • Teriflunomide antifolate: Methotrexate Macrolides/ other IL-2 inhibitors FKBP/Cyclophilin/Calcineurin: Tacrolimus • Ciclosporin • Pimecrolimus Abetimus • Gusperimus TNF-α inhibitor Thalidomide • Lenalidomide Intracellular (reception) IL-1 receptor antagonists Anakinra mTOR Sirolimus • Deforolimus • Everolimus • Temsirolimus • Zotarolimus • Biolimus A9 Extracellular Antibodies Monoclonal Serum target (noncellular) Complement component 5 (Eculizumab) • TNFs (Infliximab, Adalimumab, Certolizumab pegol, Afelimomab, Golimumab) • Interleukin 5 (Mepolizumab) • Immunoglobulin E (Omalizumab)  • BAYX (Nerelimomab) Interferon (Faralimomab) IL-6 (Elsilimomab) IL-12 and IL-23 (Lebrikizumab, Ustekinumab) Cellular target CD3 (Muromonab-CD3, Otelixizumab, Teplizumab, Visilizumab) • CD4 (Clenoliximab, Keliximab, Zanolimumab) • CD11a (Efalizumab) • CD18 (Erlizumab) • CD20 (Afutuzumab, Rituximab, Ocrelizumab, Pascolizumab) • CD23 (Lumiliximab) • CD40 (Teneliximab, Toralizumab) • CD62L/L-selectin (Aselizumab) • CD80 (Galiximab) • CD147/Basigin (Gavilimomab) • CD154 (Ruplizumab) BLyS (Belimumab)  • CTLA-4 (Ipilimumab, Tremelimumab) • CAT (Bertilimumab, Lerdelimumab, Metelimumab) • Integrin (Natalizumab) • Interleukin-6 receptor (Tocilizumab) • LFA-1 (Odulimomab) IL-2 receptor/CD25 (Basiliximab, Daclizumab, Inolimomab) T-lymphocyte (Zolimomab aritox) Unsorted Atorolimumab, Cedelizumab, Dorlixizumab, Fontolizumab, Gantenerumab, Gomiliximab, Maslimomab, Morolimumab, Pexelizumab, Reslizumab, Rovelizumab, Siplizumab, Talizumab, Telimomab aritox, Vapaliximab, Vepalimomab Polyclonal Anti-thymocyte globulin • Anti-lymphocyte globulin -cept (Fusion) CTLA-4 (Abatacept, Belatacept) • TNF inhibitor (Etanercept, Pegsunercept) • Aflibercept • Alefacept • Rilonacept M: LMC cell/phys/auag/auab/comp, igrc imdf/ipig/hyps/tumr proc, drug(L3/4) v · d · eMonoclonal antibodies for the immune system Immune system ("-l(i[m])-") Human ("-limu-") immunosuppression: Adalimumab • Atorolimumab • Fresolimumab • Golimumab • Lerdelimumab • Metelimumab • Morolimumab immune activation: Ipilimumab • Tremelimumab other: Bertilimumab • Zanolimumab Mouse ("-limo-") Afelimomab • Elsilimomab • Faralimomab • Gavilimomab • Inolimomab • Maslimomab • Nerelimomab • Odulimomab • Telimomab aritox • Vepalimomab • Zolimomab aritox Chimeric ("-lixi-") Basiliximab • Clenoliximab • Galiximab • Gomiliximab • Infliximab • Keliximab • Lumiliximab • Priliximab • Teneliximab • Vapaliximab Humanized ("-lizu-") immunosuppressive: Aselizumab • Apolizumab • Benralizumab† • Cedelizumab • Certolizumab pegol • Daclizumab • Eculizumab • Efalizumab • Epratuzumab • Erlizumab • Fontolizumab • Mepolizumab • Natalizumab • Ocrelizumab • Omalizumab • Pascolizumab • Pexelizumab • PRO 140† • Reslizumab • Rontalizumab • Rovelizumab • Ruplizumab • Siplizumab • Talizumab • Teplizumab • Tocilizumab • Toralizumab • Vedolizumab • Visilizumab • TGN1412§ non-immunosuppressive: Ibalizumab† Chimeric + humanized ("-lixizu-") Dorlixizumab • Otelixizumab Interleukin ("-k(i[n])-") Human ("-kinu-") Briakinumab • Canakinumab • Ustekinumab Humanized ("-kizu-") Lebrikizumab Inflammatory lesions ("-les-") Mouse ("-leso-") Besilesomab • Fanolesomab‡ • Lemalesomab • Sulesomab #WHO-EM. ‡Withdrawn from market. Clinical trials: †Phase III. §Never to phase III M: LMC cell/phys/auag/auab/comp, igrc imdf/ipig/hyps/tumr proc, drug(L3/4) This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.v · d · e This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.v · d · e